MedTrace Logo

Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan

NCT04871841 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2024-04-12

No results posted yet for this study

Summary

This study will assess the safety, reactogenicity, and immunogenicity of Gam-COVID-Vac (Sputnik V) vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). The vaccine contains two recombinant adenoviral vectors harbouring SARS-CoV-2 Spike gene. The vaccine will be administered intramuscularly on a 2-dose prime-boost schedule. Participants will be healthy adults aged greater than or equal to 18 years, voluntarily undergoing vaccination according to the guidelines of the Ministry of Healthcare of Kazakhstan.

Conditions

  • Covid19
  • Vaccine Adverse Reaction

Interventions

BIOLOGICAL

Sputnik V

Participants will receive intramuscular (IM) injection of a single dose of rAd26-S and rAd5-S at day 0 and day 21, respectively.

Sponsors & Collaborators

Principal Investigators

  • Irina Kadyrova, MD, PhD · Research Centre, Karaganda Medical University

  • Sergey Yegorov, PhD · McMaster University, Hamilton, Canada

  • Anar Turmukhambetova, MD/DMS · Karaganda Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-05
Primary Completion
2021-09-05
Completion
2023-06-20

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871841 on ClinicalTrials.gov